Spain · Delayed Price · Currency is EUR Oryzon Genomics Statistics
Total Valuation
Oryzon Genomics has a market cap or net worth of EUR 232.07 million. The enterprise value is 221.47 million.
| Market Cap | 232.07M |
| Enterprise Value | 221.47M |
Important Dates
The next estimated earnings date is Tuesday, July 28, 2026.
| Earnings Date | Jul 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Oryzon Genomics has 77.51 million shares outstanding. The number of shares has increased by 19.72% in one year.
| Current Share Class | 77.51M |
| Shares Outstanding | 77.51M |
| Shares Change (YoY) | +19.72% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 13.92% |
| Owned by Institutions (%) | 1.55% |
| Float | 60.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 21.22 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -99.12 |
| EV / Sales | 20.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -15.09% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 6.68% |
| Revenue Per Employee | 237,705 |
| Profits Per Employee | -48,571 |
| Employee Count | 46 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.99M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.53% in the last 52 weeks. The beta is 0.44, so Oryzon Genomics's price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | +2.53% |
| 50-Day Moving Average | 2.87 |
| 200-Day Moving Average | 3.05 |
| Relative Strength Index (RSI) | 53.15 |
| Average Volume (20 Days) | 471,104 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oryzon Genomics had revenue of EUR 10.93 million and -2.23 million in losses. Loss per share was -0.03.
| Revenue | 10.93M |
| Gross Profit | 10.65M |
| Operating Income | -8.24M |
| Pretax Income | -5.23M |
| Net Income | -2.23M |
| EBITDA | -8.12M |
| EBIT | -8.24M |
| Loss Per Share | -0.03 |
Balance Sheet
| Cash & Cash Equivalents | n/a |
| Total Debt | n/a |
| Net Cash | n/a |
| Net Cash Per Share | n/a |
| Equity (Book Value) | n/a |
| Book Value Per Share | n/a |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 115,788 |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 97.42%, with operating and profit margins of -75.34% and -20.43%.
| Gross Margin | 97.42% |
| Operating Margin | -75.34% |
| Pretax Margin | -47.81% |
| Profit Margin | -20.43% |
| EBITDA Margin | -74.28% |
| EBIT Margin | -75.34% |
| FCF Margin | n/a |
Dividends & Yields
Oryzon Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.72% |
| Shareholder Yield | -19.72% |
| Earnings Yield | -0.96% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Oryzon Genomics is 7.13, which is 138.14% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 7.13 |
| Price Target Difference | 138.14% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 95.56% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |